MXCT vs NVR · rev $38.6M vs P/E 15, rev $10.52B
MaxCyte Inc (MXCT) versus NVR Inc (NVR) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
NVR Inc (NVR) is a residential construction company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NVR revenue for 2024-12-31 was $10.52B. Net income was $1.68B. Revenue was up 10.6% from 2023-12-31 to 2024-12-31. NVR currently screens at market cap $16.94B and trailing P/E 15.3.
MXCT currently screens at market cap $124.3M. NVR currently screens at market cap $16.94B and trailing P/E 15.3.
Not investment advice. Open the MXCT and NVR stock pages for the full models.
Not investment advice.